| Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder A Mørk, A Pehrson, LT Brennum, SM Nielsen, H Zhong, AB Lassen, ... Journal of Pharmacology and Experimental Therapeutics 340 (3), 666-675, 2012 | 353 | 2012 |
| Psychiatric and neuropsychiatric sequelae of COVID-19–A systematic review TM Schou, S Joca, G Wegener, C Bay-Richter Brain, behavior, and immunity 97, 328-348, 2021 | 344 | 2021 |
| Reference genes for normalization: a study of rat brain tissue BE Bonefeld, B Elfving, G Wegener Synapse 62 (4), 302-309, 2008 | 284 | 2008 |
| The flinders sensitive line rat model of depression—25 years and still producing DH Overstreet, G Wegener Pharmacological reviews 65 (1), 143-155, 2013 | 239 | 2013 |
| Stress–restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus BH Harvey, F Oosthuizen, L Brand, G Wegener, DJ Stein Psychopharmacology 175, 494-502, 2004 | 213 | 2004 |
| Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo G Wegener, V Volke, R Rosenberg British journal of pharmacology 130 (3), 575-580, 2000 | 210 | 2000 |
| Cannabidiol induces rapid and sustained antidepressant-like effects through increased BDNF signaling and synaptogenesis in the prefrontal cortex AJ Sales, MV Fogaça, AG Sartim, VS Pereira, G Wegener, FS Guimarães, ... Molecular neurobiology 56 (2), 1070-1081, 2019 | 202 | 2019 |
| Central functions of neuropeptide Y in mood and anxiety disorders G Wu, A Feder, G Wegener, C Bailey, S Saxena, D Charney, AA Mathé Expert opinion on therapeutic targets 15 (11), 1317-1331, 2011 | 200 | 2011 |
| Animal models of depression and anxiety: What do they tell us about human condition? ID Neumann, G Wegener, JR Homberg, H Cohen, DA Slattery, J Zohar, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 35 (6), 1357-1375, 2011 | 194 | 2011 |
| Antidepressant-and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice V Volke, G Wegener, M Bourin, E Vasar Behavioural brain research 140 (1-2), 141-147, 2003 | 194 | 2003 |
| Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity G Wegener, V Volke, BH Harvey, R Rosenberg Brain research 959 (1), 128-134, 2003 | 187 | 2003 |
| Probiotic treatment reduces depressive-like behaviour in rats independently of diet A Abildgaard, B Elfving, M Hokland, G Wegener, S Lund Psychoneuroendocrinology 79, 40-48, 2017 | 185 | 2017 |
| Repeated electroconvulsive seizures increase the total number of synapses in adult male rat hippocampus F Chen, TM Madsen, G Wegener, JR Nyengaard European neuropsychopharmacology 19 (5), 329-338, 2009 | 184 | 2009 |
| Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression PA Melas, M Rogdaki, A Lennartsson, K Björk, H Qi, A Witasp, M Werme, ... International Journal of Neuropsychopharmacology 15 (5), 669-679, 2012 | 164 | 2012 |
| Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats IL Heiberg, G Wegener, R Rosenberg Behavioural brain research 134 (1-2), 479-484, 2002 | 158 | 2002 |
| Antidepressant-Like Effect of Sodium Butyrate is Associated with an Increase in TET1 and in 5-Hydroxymethylation Levels in the Bdnf Gene YB Wei, PA Melas, G Wegener, AA Mathé, C Lavebratt International Journal of Neuropsychopharmacology 18 (2), pyu032, 2015 | 152 | 2015 |
| Stress and corticosterone increase the readily releasable pool of glutamate vesicles in synaptic terminals of prefrontal and frontal cortex G Treccani, L Musazzi, C Perego, M Milanese, N Nava, T Bonifacino, ... Molecular Psychiatry 19 (4), 433-443, 2014 | 136 | 2014 |
| Detection of brain-derived neurotrophic factor (BDNF) in rat blood and brain preparations using ELISA: pitfalls and solutions B Elfving, PH Plougmann, G Wegener Journal of neuroscience methods 187 (1), 73-77, 2010 | 136 | 2010 |
| Inverse correlation of brain and blood BDNF levels in a genetic rat model of depression B Elfving, PH Plougmann, HK Müller, AA Mathé, R Rosenberg, ... International Journal of Neuropsychopharmacology 13 (5), 563-572, 2010 | 132 | 2010 |
| Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase A Petzer, BH Harvey, G Wegener, JP Petzer Toxicology and applied pharmacology 258 (3), 403-409, 2012 | 117 | 2012 |
